TrialDiabetologia2020

The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.

Caroline T B Juel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.